NEW YORK (Reuters Health)—Monotherapy with the JAK1-selective inhibitor upadacitinib is effective in patients with active rheumatoid arthritis who have an inadequate response to methotrexate, according to results from the SELECT-MONOTHERAPY phase 3 trial. As many as two-thirds of patients with rheumatoid arthritis receiving methotrexate monotherapy fail to achieve satisfactory disease control. Oral therapy with upadacitinib…
FDA Approves Risankizumab, Adds Stronger Warning to Sleep Medications
The FDA has approved rizankixumab to treat adults with plaque psoriasis and added boxed warnings to sleep medications…
British Columbia Will Be First Canadian Province to Switch Patients to Biosimilars
TORONTO/MONTREAL (Reuters)—The Canadian province of British Columbia said on May 28 that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million) over three years. The new policy from the province’s PharmaCare program targets Johnson & Johnson’s…
WHO Drug Pricing Talks May Fail to End Secrecy, Activists Fear
GENEVA (Reuters)—Governments are working on a drug pricing transparency deal at the World Health Organization’s (WHO) annual assembly, but activists said on Thursday they fear crucial costs may be left out, enabling pharmaceutical firms to keep prices high. Campaigners say some drugs are exhorbitantly priced, even though they are often developed with public funding, and…
U.S. Supreme Court Tosses Ruling Against Merck on Fosamax Osteoporosis Drug
WASHINGTON (Reuters)—On May 20, the U.S. Supreme Court threw out a lower court ruling that had revived hundreds of lawsuits accusing Merck & Co. of failing to properly warn patients of debilitating thigh-bone fractures as a result of taking its osteoporosis drug alendronic acid (Fosamax). The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit…
Ixekizumab Promising for Non-Radiographic Axial SpA; Plus FDA Approves Belimumab for Pediatric Lupus
Results from a Phase 3 study showed ixekizumab significantly improved the signs and symptoms of non-radiographic axial spondyloarthritis in patients…
Common Characteristics in RA Patients Who Don’t Respond to Biologics
At least 6% of patients who used biologic disease-modifying anti-rheumatic drugs (bDMARDs) suffered refractory disease, according to a recent study based on data from the British Society for Rheumatology Biologics Registry for Rheumatoid Arthritis.1 This observational study evaluated the extent of biologic refractory rheumatoid arthritis (RA). The study defined biologic refractory disease as occurring in…
Rheumatology Drugs at a Glance, Part 2: Psoriasis
Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…
IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…
Trump Slams Drugmakers, Vows to Let U.S. States Buy Cheaper Medicines Abroad
WASHINGTON (Reuters)—U.S. President Donald Trump slammed the pharmaceutical industry for high prices of prescription drugs on Thursday and vowed to allow U.S. states to buy medicines from other countries if they cost less. Trump, who campaigned on a platform to reduce drug prices for U.S. consumers, has taken few concrete steps to lower medication costs…
- « Previous Page
- 1
- …
- 34
- 35
- 36
- 37
- 38
- …
- 120
- Next Page »